National Institute for Pharmaceutical Technology and Education (NIPTE) Interim Risk Assessment Report.

Slides:



Advertisements
Similar presentations
Stability Studies - Evaluation of Outcomes and Development of Documentation For Regulatory Submissions Bob Seevers.
Advertisements

 AUTHOR- Musiba Baliruno Denis, B.pharm (MUST) SUPERVISORS ;  Prof. K.A.M. Kuria, PhD - Department of Pharmaceutics and Pharmacy Practice, University.
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Training Workshop on Pharmaceutical Development.
2-5. Formulation Development Issues: Solid Orals Satish Mallya January, 2011.
Methods of tablet manufacturing
Wet Granulation Scale-up Experiments. Scale-up Approach with Dimensional Numbers 2 The effect of process parameter (i.e., impeller speed, liquid addition.
BY: Chris Tremblay.  Piece of equipment used to remove moisture from a wet solid by bringing the moisture into a gaseous state.  A drying medium (usually.
Quality by Design (QbD) in Product Development
Six Sigma Quality Engineering
Tony Gould Quality Risk Management. 2 | PQ Workshop, Abu Dhabi | October 2010 Introduction Risk management is not new – we do it informally all the time.
Annex I: Methods & Tools prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY.
ICH Q9: Quality Risk Management
Multi station rotary presses
Learnings from Pre-approval Joint Inspection of a GSK QbD Product with US-FDA & EMA and the application of Continuous Verification 17 May 2011, Beijing,
DEVELOPMENT OF QUALITY BY DESIGN (QBD) GUIDANCE ELEMENTS ON DESIGN SPACE SPECIFICATIONS ACROSS SCALES WITH STABILITY CONSIDERATIONS Scale up consideration.
A Seminar on 1.  Why to validate?  Parts of Equipment Validation  Who should do Equipment Validation?  Equipment qualification  Typical process flow.
Quality Risk Management Methodology Anthony Cumberlege SAPRAA meeting - Randpark golf club, 20 March 2009.
Carl A. Anderson, Ph.D. James K. Drennen, III, Ph. D.
Quality by Design Application of Pharmaceutical QbD for Enhancement of the Solubility and Dissolution of a Class II BCS Drug using Polymeric Surfactants.
DEVELOPMENT OF QUALITY BY DESIGN (QBD) GUIDANCE ELEMENTS ON DESIGN SPACE SPECIFICATIONS ACROSS SCALES WITH STABILITY CONSIDERATIONS Fluid Bed Drying Small.
Effects and impacts of components of coal handling system on coke quality and yield of coke plants S. Steinbach, R. Neuwirth, Dr.
Module 1, Part 3: Process validation Slide 1 of 22 © WHO – EDM – 12/2001 Validation Part 3: Process validation Supplementary Training Modules on Good Manufacturing.
NIPTE-FDA Collaborative Case Study On Model-based Design Space Development Across Scales & with Stability Considerations Preliminary Design Space 1.
1-7.The ICH Q8 “Minimal Approach” to Pharmaceutical Development
Quality control Lecture 1.
Novel Multifunctional Excipients by Co-processing with Mg-Silicate Dr. Faisal Al-Akayleh Faculty of Pharmacy, Petra University.
QUALITY RISK MANAGEMENT RASHID MAHMOOD MSc. Analytical Chemistry MS in Total Quality Management Senior Manager Quality Assurance Nabiqasim Group of Industries.
Formulation factors By Dr. A. S. Adebayo.
DEVELOPMENT OF QUALITY BY DESIGN (QBD) GUIDANCE ELEMENTS ON DESIGN SPACE SPECIFICATIONS ACROSS SCALES WITH STABILITY CONSIDERATIONS Blending Benoit Igne,
Linking Drug Stability to Manufacturing Risk Assessment Approaches L. E. Kirsch Stability team leader.
DEVELOPMENT OF QUALITY BY DESIGN (QBD) GUIDANCE ELEMENTS ON DESIGN SPACE SPECIFICATIONS ACROSS SCALES WITH STABILITY CONSIDERATIONS Scale-up Experimentation.
Critical Material Properties for Pharmaceutical Dosage Forms - Industry Perspective Tony Hlinak Abbott Laboratories North Chicago, IL.
PMP Study Guide Chapter 6: Risk Planning. Chapter 6 Risk Planning Planning for Risks Plan Risk Management Identifying Potential Risk Analyzing Risks Using.
NIPTE-FDA Collaborative Case Study On Model-based Design Space Development Across Scales & with Stability Considerations Design Space Integration 1.
Satish Mallya January 20-22, |1 | 2-3. Pharmaceutical Development Satish Mallya Quality Workshop, Copenhagen May 18-21, 2014 May 18-21,2014.
General Aspects of Quality assessment of multisource interchangeable medicines Rutendo Kuwana Technical Officer, WHO, Geneva Training workshop: Assessment.
GRANULATION DR. MOHAMMAD KHALID ANWER Assistant Professor 2/25/20161 COLLEGE OF PHARMACY, PRINCE SATTAM BIN ABDULAZIZ UNIVERSITY.
Tablet Granulation. Introduction  Granulation is the process in which primary powder particles are made to adhere to form larger, multi particle entities.
Quality control Lecture 1.
开发报批美国 FDA 的仿制药 与相关问题探讨 上海复星普适医药科技有限公司何平. 内容提要 开发仿制药的重要性和机遇 开发仿制药的重要性和机遇 开发仿制药的挑战 开发仿制药的挑战 申报仿制药的分类 申报仿制药的分类 仿制药研发团队 仿制药研发团队 仿制药的研发过程 仿制药的研发过程 QbD 在制剂开发中怎么体现.
Supplier Performance Development Process
QbD Technologies: Workshop for Risks Management Incorporating Risk Management for Technology Transfer.
ON “SOFTWARE ENGINEERING” SUBJECT TOPIC “RISK ANALYSIS AND MANAGEMENT” MASTER OF COMPUTER APPLICATION (5th Semester) Presented by: ANOOP GANGWAR SRMSCET,
TABLET GRANULATION TECHNIQUES.
QbD Technologies: Workshop for Risks Management Incorporating Risk Management for Technology Transfer.
Integration of Excipients into the Design of Experiments for Pharmaceutical Product and Design Space Development Chris Moreton, Ph.D. FinnBrit Consulting.
Faculty of Pharmacy and Medical Sciences Al-Ahliyya Amman University
Proposal for a Manufacturing Classification System (MCS)
A QbD Approach to Process Development: Defining Critical Quality Attributes and Evaluating Criticality Across Scales Carl A. Anderson, Duquesne University.
QbD in PLCM Presented By: Mr. Girish Sonar,
Enabling direct compaction at high drug loading via dry coating of APIs: Towards a predictive framework Presenter(s): Kuriakose T. Kunnath, NJIT Research.
Total Quality Management Quality Risk Management
FMEA PROCESS FLOW Determine Causes/ mechanisms failure
Quality Risk Management
INTRODUCTION Granulation process has been widely used in the pharmaceutical industry for the preparation of material for tabletting. Other Granulation.
Dr Dehghan M. H Professor in Pharmaceutics,
Group members: Firdaus | Sofia | Nurainiza | Hafizah
QbD Risk analysis for process evaluation
Wet Granulation Small Scale Experiments
Supplier Performance Development Process
Quality Control Requirement
ICH Q9: Quality Risk Management
ICH Q9: Quality Risk Management
Tablet Dosage Form Lab 1.
Lab 3 Industrial pharmacy
HHV 5014 Nutraceutical formulation technology
Quality by Design.
Aram I. Ibrahim University of sulaimani College of pharmacy
POWDER AND GRANULES FADHILAH FAIROZA FATIN HUSNA
Tablets.
Presentation transcript:

National Institute for Pharmaceutical Technology and Education (NIPTE) Interim Risk Assessment Report

Quality Risk Management Initiate Quality Risk Management Process Risk Assessment Risk Control Risk Review Risk Identification Risk Analysis Risk Evaluation Risk Reduction Risk Acceptance Review Events Output / Result of the Quality Risk Management Process Risk Communication Risk Management Tools unacceptable Brainstorming Elementary Cause and Effect Assignments –Fishbone (Ishikawa) diagram –Failure mode/effect table Fault tree analysis Process map Flow charts FMEA FMECA Risk ranking Risk IdentificationRisk Analysis Risk Evaluation Process sensors SOP Data flow optimization Risk Reduction From ICH Q9

3 Formulation Gabapentin600 mg Poloxamer 407, NF11 mg Crospovidone NF22 mg Pregelatinized corn starch, NF 60 mg Mg Stearate, NF7 mg MCC NF (Avicel PH102)100 mg Talc USP Extra-fine9 mg Hydroxypropyl cellulose 40 mg Hydroxypropyl cellulose 40 mg (Binder )

4 Preliminary Risk Assessment Critical quality attributes –Content uniformity –Assay –Disintegration –Physical form of API –Physical stability of API –Purity –Chemical stability –Microbiology –Appearance Unit operations –Binder solution preparation –Granulation –Drying –Granulate shipping –Blending –Compression

Example of Failure Mode Table SODRPN EffectCause Effect (CQA) tablets Mechanism of effectScale-upUnit opCause Disintegration Homogeneity of HPCxBlendingInadequate blending Physical form API Hydrate formation during ProcessingxGranulationTime as wet mass The (CQA) test is out of specification because (mechanism of effect). The source of the problem is in (Unit operation) and is caused by (Cause1), caused by (Cause2), caused by (Cause3).

Histogram of all Failure Modes Assessed (RPN values) Medium High High: > 60 Medium: = 60

Preliminary RPN Results: Risks sorted by Unit Operation Binder solution preparation –Number of risks assessed:11 –No high or medium risk failure modes Granulation –Number of risks assessed:75 –High risk failure modes:13 /75 –Medium risk failure modes:20 /75 Fluid bed drying –Number of risks assessed:30 –High risk failure modes:3 /30 –Medium risk failure modes:16 /30

QbD Approach to Formulation Optimization The original HPC grade (Klucel EXF, fine PSD) was sensitive to small changes in water content (lacking robustness) A second HPC grade (Klucel EF, larger PSD) was more robust. Similar PSDs were achieved using Klucel EF at 5.5% water as with Klucel EXF at 2.5%.

Comparing Granule PSD Produced from Different HPC Grades Particle size distribution Granules formed with EF and 5.5% water were similar to granules formed with EXF and 2.5% water

Drying of Wet Granulations with 2 Different Grades of HPC Water added 5.5%4%3%2.5%2% EF ✔✔ ✔ Little Particle Size Growth ✔ Little Particle Size Growth ✔ Little Particle Size Growth EXF No fluidization ✔✔

Klucel EXF vs. Klucel EF Klucel EXF Klucel EF

FBD Stability Concerns (Example Process Models and Design Space)

Summary of Drying Stability Specs Residual moisture stabilizes granules and blends from lactam formation –Some residual moisture is good to decrease lactam formation, but too much residual moisture has flow and hardness consequences, which could result in content uniformity and disintegration problems. High temperature drying results in higher lactam formation. –There was no improvement in efficiency by drying at higher temperatures due to increased cooling times, so low temperature drying is optimum.

Lab Scale Compression Data (Rotary Press) By changing the extragranular HPC from Klucel EF (larger PS), to Klucel EXF (Fine PS), the crushing strength threshold of 6 kp was achieved.

Additional Assessment Efforts Evaluate all stability data Update design space models at each scale –Develop design space model across scales Identify and document –Risks to product quality –Advantages of current methods for reducing risk Modeling Process monitoring/control